Unleashing immuno-mass spectrometry superpowers to detect SARS-CoV-2.
other
Where this comes from
- Record sourced from PubMed, PMID 34252697.
- Also identified by DOI 10.1016/j.ebiom.2021.103480 and PMC identifier 8270654.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In this article of EBioMedicine, Santosh Renuse and colleagues<sup>1</sup> show the relevance of combining immunoaffinity capture with targeted mass spectrometry measurement to detect SARS-CoV-2 nucleocapsid proteins in nasopharyngeal swab samples. The COVID-19 pandemic has confirmed the need to improve the toolbox available to diagnose respiratory infections. Rapid, reliable, and highly specific detection is essential if we are to mount immediate preventive and therapeutic responses. This report stands out from previous studies as it implements immunocapture along with robust validation for a large cohort of subjects. The results presented show that mass spectrometry is definitively at a crossroads for large-scale clinical applications.
Medical subject headings
- COVID-19
- SARS-CoV-2